August 1, 2025
avatar-torie-bosch
First Opinion editor

This week, First Opinion published a controversial essay about Vinay Prasad, the recently departed head of the FDA’s Center for Biologics Evaluation and Research. (My colleague Lizzy Lawrence wrote a must-read story on exactly what happened to Prasad. Don’t miss the last line.)

Adam Cifu — Prasad’s former professor and colleague at the outlet “Sensible Medicine” — praised his friend while acknowledging that he “has strong opinions, and he is not shy about sharing them. On social media, he has at times been brash, nasty, and insulting.” Cifu goes on to discuss Prasad’s short tenure at CBER and mourn how it came to an end: “Unfortunately, as difficult decisions were made, politics and pharmaceutical company money seem to have trumped the need to ensure that drugs are safe and effective.”

The piece garnered some criticism online from critics who said that Cifu is conflicted because of his relationship with Prasad. Others simply did not want to read anything in favor of Prasad.

But I’m glad that STAT published the essay. As usual, I want pieces that go against the grain, that bring a new perspective, and sometimes make people mad. And I think it’s important to publish essays that are by the people most familiar with the topic. That often means working with authors who have a conflict of some sort — and we share that with readers right up front. (I also try to sniff out any potential conflicts that we don’t know about, through STAT’s perhaps annoyingly thorough First Opinion author agreement.)

As I often tell people who are interested in learning more about First Opinion, “Every piece should make someone in STAT’s readership mad.” If everyone agrees, what’s the point of persuasive writing?

Recommendation of the week: The podcast “Devil in the Dorm,” about the so-called “Sarah Lawrence sex cult.” Narrated by Elisabeth Röhm, an alumna of both Sarah Lawrence and original-recipe “Law & Order,” it’s equal parts horrifying and compelling. One of the victims, a graduate of Columbia Medical School, fell under the conman/leader’s sway while a psychiatry resident at UCLA, showing how even the highly educated can be at risk under the right circumstances.



LOIC VENANCE/AFP via Getty Images

What I learned by going off SSRIs after nearly a decade

STAT’s Sarah Todd happened to go off escitalopram amid new public scrutiny of antidepressants. Here’s what she found.

By Sarah Todd


I’m a neurologist. My brother has schizophrenia. I support making involuntary commitment easier

U.S. needs a legal, medical framework that allows us to treat not just the willing, but the vulnerable, writes neurologist whose brother has schizophrenia.

By Shaheen E. Lakhan


The U.S. needs a revolution to harness the potential of GLP-1s for weight loss

Where is the national plan to facilitate the widespread, safe delivery to eligible Americans of GLP-1s like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound?

By Gavin Hart


ADOBE

The FDA’s plan on fluoride supplements is bad science

The FDA says it expects to remove prescription fluoride supplements from the market after completing a review. But a predetermined outcome is bad science.

By Peter J. Pitts


Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine

It is ironic, or maybe fitting, that Vinay Prasad’s downfall seems related to a Sarepta drug, Elevidys, that is neither safe nor effective.

By Adam Cifu


Medical students must be able to voice ethical concerns during clinical rotations

With the current assessment structure, medical students’ attention is pulled toward impressing doctors and administrators instead of patients.

By Chad Childers


ADOBE

The Vaccine Injury Compensation Program needs to be updated, not eliminated

Eliminating the Vaccine Injury Compensation Program would hurt people with valid claims of being harmed by a vaccine.

By Dorit R. Reiss and Arthur L. Caplan


Learning to say no in a medical system that always asks physicians for more, more, more

Medicine, academia weren’t designed to be sustained by sheer willpower, especially not while navigating disabilities, chronic illness, caregiving, or loss.

By Cara Poland


STAT+ | How the FDA can score quick wins on transparency

Upgrading how the FDA stores public data and documents about already-approved drugs would be a transparency win.

By Frank David


CHANDAN KHANNA/AFP via Getty Images

STAT+ | U.S. must develop plan to protect clinical trials as national security asset

The U.S. clinical trial infrastructure stands as a key pillar of both our health security and our global strategic leadership.

By Andrew Barnhill and Abraham Sinay-Smith


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.